1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mechanism of erythropoietin-induced hypertension.

      American Journal of Kidney Diseases
      Anemia, complications, drug therapy, Animals, Catecholamines, blood, Endothelins, Erythrocyte Volume, Erythropoietin, adverse effects, pharmacology, therapeutic use, Hematocrit, Humans, Hypertension, chemically induced, etiology, Kidney Failure, Chronic, Renin-Angiotensin System, physiology, Time Factors, Vasoconstrictor Agents

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chronic administration of erythropoietin (EPO) is associated with an increase in arterial blood pressure in patients and animals with chronic renal failure (CRF). Several mechanisms have been considered in the pathogenesis of EPO-induced hypertension. These include the possible role of the rise of hematocrit and erythrocyte mass, changes in production or sensitivity to endogenous vasopressors, alterations in vascular smooth-muscle ionic milieu, dysregulation of production or responsiveness to endogenous vasodilatory factors, a direct vasopressor action of EPO, and finally arterial remodeling through stimulation of vascular cell growth.

          Related collections

          Author and article information

          Comments

          Comment on this article